KA/EN
Register
Medicines reference
Search
Search
Product

Simparica Trio

Favourites

Sarolaner + Moxidectin + Pyrantel · Zoetis

6 forms: chewable tablet. In force in Georgia: 6 of 6 (veterinary register).

Forms and doses6 of 6 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
3 mg/0.06 mg/12.5 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >1.25-2.5კგ
№ 182-11, 34-11
Verified on: 15 Oct 2026
3 mg/0.06 mg/12.5 mg, Chewable tablet · Dog 1.25–2.5 kg Dog 1.25–2.5 kg 1 tablet
a dose of 1.2–2.4 mg/kg of sarolaner, 0.024–0.048 mg/kg of moxidectin and 5–10 mg/kg of pyrantel In the absence of the risk of mixed co-infestation, a narrower spectrum parasiticide should be used. minimum 1-month interval the recommended dose should be strictly observed not recommended
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >1.25-2.5კგ
№ 182-11, 34-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica Trio 3 mg/0.06 mg/12.5 mg, Chewable tablet

sarolaner 3 mg + moxidectin 0.06 mg + pyrantel (as embonate) 12.5 mg, chewable tablet for dogs 1.25-2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

3 mg/0.06 mg/12.5 mg, sarolaner 3 mg + moxidectin 0.06 mg + pyrantel (as embonate) 12.5 mg, chewable tablet for dogs 1.25-2.5 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 182-11, 34-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner3 mg Moxidectin0.06 mg Pyrantel12.5 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >1.25-2.5კგ
№ 182-11, 34-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
a dose of 1.2–2.4 mg/kg of sarolaner, 0.024–0.048 mg/kg of moxidectin and 5–10 mg/kg of pyrantel In the absence of the risk of mixed co-infestation, a narrower spectrum parasiticide should be used. minimum 1-month interval the recommended dose should be strictly observed not recommended
 Dog 1.25–2.5 kg By mouth monthly Product label (SPC)
6 mg/0.12 mg/25 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >2.5-5კგ
№ 180-11, 404-11
Verified on: 15 Oct 2026
6 mg/0.12 mg/25 mg, Chewable tablet · Dog 2.5–5 kg Dog 2.5–5 kg 1 tablet
Give 1 whole Simparica Trio tablet of the specified strength monthly to a dog weighing over 2.5 kg up to 5 kg. Use only when the combined antiparasitic spectrum is indicated, follow the weight band exactly in MDR1-sensitive breeds, and do not divide the tablet.
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >2.5-5კგ
№ 180-11, 404-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica Trio 6 mg/0.12 mg/25 mg, Chewable tablet

sarolaner 6 mg + moxidectin 0.12 mg + pyrantel (as embonate) 25 mg, chewable tablet for dogs 2.5-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

6 mg/0.12 mg/25 mg, sarolaner 6 mg + moxidectin 0.12 mg + pyrantel (as embonate) 25 mg, chewable tablet for dogs 2.5-5 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 180-11, 404-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner6 mg Moxidectin0.12 mg Pyrantel25 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >2.5-5კგ
№ 180-11, 404-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Give 1 whole Simparica Trio tablet of the specified strength monthly to a dog weighing over 2.5 kg up to 5 kg. Use only when the combined antiparasitic spectrum is indicated, follow the weight band exactly in MDR1-sensitive breeds, and do not divide the tablet.
 Dog 2.5–5 kg By mouth monthly Product label (SPC)
12 mg/0.24 mg/50 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >5-10კგ
№ 185-11, 406-11
Verified on: 15 Oct 2026
12 mg/0.24 mg/50 mg, Chewable tablet · Dog 5–10 kg Dog 5–10 kg 1 tablet
Simparica Trio Chewable Tablets for Dogs >5–10 kg
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >5-10კგ
№ 185-11, 406-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica Trio 12 mg/0.24 mg/50 mg, Chewable tablet

sarolaner 12 mg + moxidectin 0.24 mg + pyrantel (as embonate) 50 mg, chewable tablet for dogs 5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

12 mg/0.24 mg/50 mg, sarolaner 12 mg + moxidectin 0.24 mg + pyrantel (as embonate) 50 mg, chewable tablet for dogs 5-10 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 185-11, 406-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner12 mg Moxidectin0.24 mg Pyrantel50 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >5-10კგ
№ 185-11, 406-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica Trio Chewable Tablets for Dogs >5–10 kg
 Dog 5–10 kg By mouth monthly Product label (SPC)
24 mg/0.48 mg/100 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >10-20კგ
№ 184-11, 403-11
Verified on: 15 Oct 2026
24 mg/0.48 mg/100 mg, Chewable tablet · Dog 10–20 kg Dog 10–20 kg 1 tablet
Simparica Trio Chewable Tablets for Dogs >10–20 kg
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >10-20კგ
№ 184-11, 403-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica Trio 24 mg/0.48 mg/100 mg, Chewable tablet

sarolaner 24 mg + moxidectin 0.48 mg + pyrantel (as embonate) 100 mg, chewable tablet for dogs 10-20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

24 mg/0.48 mg/100 mg, sarolaner 24 mg + moxidectin 0.48 mg + pyrantel (as embonate) 100 mg, chewable tablet for dogs 10-20 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 184-11, 403-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner24 mg Moxidectin0.48 mg Pyrantel100 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >10-20კგ
№ 184-11, 403-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica Trio Chewable Tablets for Dogs >10–20 kg
 Dog 10–20 kg By mouth monthly Product label (SPC)
48 mg/0.96 mg/200 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >20-40კგ
№ 179-11, 402-11
Verified on: 15 Oct 2026
48 mg/0.96 mg/200 mg, Chewable tablet · Dog 20–40 kg Dog 20–40 kg 1 tablet
Simparica Trio Chewable Tablets for Dogs >20–40 kg
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >20-40კგ
№ 179-11, 402-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica Trio 48 mg/0.96 mg/200 mg, Chewable tablet

sarolaner 48 mg + moxidectin 0.96 mg + pyrantel (as embonate) 200 mg, chewable tablet for dogs 20-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

48 mg/0.96 mg/200 mg, sarolaner 48 mg + moxidectin 0.96 mg + pyrantel (as embonate) 200 mg, chewable tablet for dogs 20-40 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 179-11, 402-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner48 mg Moxidectin0.96 mg Pyrantel200 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >20-40კგ
№ 179-11, 402-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica Trio Chewable Tablets for Dogs >20–40 kg
 Dog 20–40 kg By mouth monthly Product label (SPC)
72 mg/1.44 mg/300 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >40-60კგ
№ 181-11, 33-11
Verified on: 15 Oct 2026
72 mg/1.44 mg/300 mg, Chewable tablet · Dog 40–60 kg Dog 40–60 kg 1 tablet
Simparica Trio Chewable Tablets for Dogs >40–60 kg >132.0 Administer the appropriate combination of tablets
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >40-60კგ
№ 181-11, 33-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica Trio 72 mg/1.44 mg/300 mg, Chewable tablet

sarolaner 72 mg + moxidectin 1.44 mg + pyrantel (as embonate) 300 mg, chewable tablet for dogs 40-60 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

72 mg/1.44 mg/300 mg, sarolaner 72 mg + moxidectin 1.44 mg + pyrantel (as embonate) 300 mg, chewable tablet for dogs 40-60 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 181-11, 33-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner72 mg Moxidectin1.44 mg Pyrantel300 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >40-60კგ
№ 181-11, 33-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica Trio Chewable Tablets for Dogs >40–60 kg >132.0 Administer the appropriate combination of tablets
 Dog 40–60 kg By mouth monthly Product label (SPC)
Active substance doses, with sources
Active substance Sarolaner
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2–4 mg/kg Dog Maintenance By mouth monthly
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Simparica 5 mg chewable tablets for dogs 1.3-2.5 kg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
Active substance Moxidectin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2.5–6.25 mg/kg Dog Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 400 mg + 100 mg spot-on solution for extra-large dogs (> 25-40 kg) - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
1–2 mg/kg Cat Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 40 mg + 4 mg spot-on solution for small cats (<= 4 kg) and ferrets - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Active substance Pyrantel
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
14.4 mg/kg Dog Maintenance By mouth once
VMD SPC 2022
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Krka Multiwormer 50/144/150 mg tablets for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2022
20 mg/kg Cat Maintenance By mouth once
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Krka Wormer 230 mg/20 mg film-coated tablets for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024

Known Contraindications

  • Critical Moxidectin
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Moxidectin (Dog)
    Do not use in puppies under 7 weeks of age. The safe use... has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.
    Sources: VMD SPC · VMD · FDA
  • Critical Moxidectin (Cat)
    Do not use in kittens under 9 weeks of age. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species.... The use is not recommended during pregnancy and lactation. Fertility: Do not use in breeding animals. The safety... has not been established in breeding, pregnant, or lactating
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin
    The use is not recommended during pregnancy and lactation.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Dog)
    special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds... in particular, oral uptake by Collie or Old English Sheep dogs and related breeds or crossbreeds should be prevented. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Dog)
    Do not use in dogs classified as Class 4 for heartworm disease has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Cat)
    use of the veterinary medicinal product on cats or ferrets which have adult heartworms may cause serious adverse effects, including death No adverse reactions were associated with the topical application... to experimentally heartworm-infected cats.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Cat)
    Do not use on sick, debilitated, or underweight cats Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using this drug.
    Sources: VMD SPC · VMD · FDA
  • Caution Moxidectin (Dog)
    Use with caution in sick, debilitated, or underweight animals.
    Sources: VMD SPC · VMD · FDA
  • Critical Pyrantel (Dog)
    Do not use in dogs younger than 2 weeks of age and/or weighing less than 2 kg.
    Sources: VMD SPC · VMD · FDA
  • Critical Pyrantel (Cat)
    Do not use in kittens less than 6 weeks of age.
    Sources: VMD SPC · VMD
  • Warning Pyrantel (Cat)
    The safety of the veterinary medicinal product has not been established during pregnancy. The product should not be used during pregnancy but may be used during lactation.
    Sources: VMD SPC · VMD
  • Critical Sarolaner
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning Sarolaner (Dog)
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. Pregnancy and lactation: The use in these animals is not recommended. Fertility: The use in breeding animals is not recommended. The safe use of SIMPARICA has not been evaluated in breeding, pregnant, or lactating dogs.
    Sources: VMD SPC · VMD · FDA
  • Warning Sarolaner (Dog)
    Pregnancy and lactation: The use in these animals is not recommended.
    Sources: VMD SPC · VMD
  • Warning Sarolaner (Dog)
    In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. less than 1.25 kg
    Sources: VMD SPC · VMD
  • Warning Sarolaner (Dog)
    The minimum age for sarolaner depends on the product label. Some labels permit use from 8 weeks, while the US Simparica label restricts use to dogs at least 6 months old because younger puppies developed neurological signs at high multiples of the dose. Follow the selected product’s label.
    Sources: VMD SPC · VMD · FDA
  • Caution Sarolaner (Dog)
    Sarolaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. mild tremors convulsions
    Sources: VMD SPC · VMD · FDA
  • Known Breed Sensitivities Moxidectin
    Collie, Collie (unspecified), Collie - Scottish Rough, Collie - Scottish Smooth, Sheepdog - Old English
    special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds... oral uptake... should be prevented.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (80 more) Hide additional products

Same therapeutic group 80

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗